ReviewThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
Neonatal Herpes Simplex Viral Infections and Acyclovir: An Update.
Review in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 62 citations in OpenAlex.
- Scalp Lesions in a Neonate.Journal of the American College of Emergency Physicians open · 2026Review
- Bidirectional transfer of pritelivir across term human placenta and its effect on placental functions.The Journal of pharmacology and experimental therapeutics · 2025Article
- Evaluation of the stability of aciclovir in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy.European journal of hospital pharmacy : science and practice · 2025Article
- Regional differences in autism and intellectual disability risk associated with cesarean section delivery.Autism research : official journal of the International Society for Autism Research · 2024Article
- Rapid diagnosis of herpes simplex virus 1 and 2 bloodstream infections utilizing a sample-to-answer platform.Journal of clinical microbiology · 2024Article
- Population pharmacokinetics and dose rationale for aciclovir in term and pre-term neonates with herpes.Pharmacology research & perspectives · 2024Article
- Challenges for early diagnosis of neonatal herpes infection in Japan.Frontiers in reproductive health · 2024Article
- Article
- Congenital anomalies during the 2015-2018 Zika virus epidemic: a population-based cross-sectional study.BMC public health · 2022Article
- The Impaired Neurodevelopment of Human Neural Rosettes in HSV-1-Infected Early Brain Organoids.Cells · 2022Article
- Herpes Simplex Virus-1 and -2 Rapid Detection in Whole Blood.Molecular diagnosis & therapy · 2021Article
- Liver Diseases in the Perinatal Period: Interactions Between Mother and Infant.Hepatology (Baltimore, Md.) · 2020Review
- Maternal immunization confers protection against neonatal herpes simplex mortality and behavioral morbidity.Science translational medicine · 2019Article
- Neonatal Sepsis.Current emergency and hospital medicine reports · 2019Review
- Economic Evaluation: Onsite HSV PCR Capabilities for Pediatric Care.Pediatric quality & safetyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neonatal herpes simplex virus (HSV) infections have high morbidity and mortality rates. Optimization of treatment and prevention strategies are imperative to improve the care and outcomes of neonates infected with HSV. Management of HSV includes reducing neonatal transmission, treating acute infections, and limiting adverse neurodevelopmental outcomes and future cutaneous outbreaks after acute infections. Transmission risk may be affected by route of delivery and maternal suppressive therapy. Neonatal HSV infections are divided into 3 categories: localized skin, eyes, or mouth; localized central nervous system; or disseminated infections. Parenteral acyclovir, the pharmacologic agent of choice, is used when treating each type of infection. However, dosage strategies and durations of therapy may vary based on disease state severity, presentation, and patient characteristics. Oral acyclovir may be used as suppressive therapy after acute treatment completion in specific neonatal populations, reducing long-term adverse neurodevelopmental outcomes and future skin eruptions. The mortality rate remains high even with treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.